JAB-23425 / Jacobio Pharma - LARVOL DELTA

Preclinical investigation of orally bioavailable, potent KRASMulti inhibitor JAB-23425 (AACR 2023) - "Our preclinical results identified JAB-23425 as a highly potent, orally bioavailable KRASMulti inhibitor, that can target multiple KRAS-driven cancers."

Preclinical • Oncology • HRAS • KRAS • NRAS

Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting (PRNewswire) - "Jacobin Pharma...announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the abstract during the American Association for Cancer Research (AACR) Annual Meeting 2023 (the 'AACR 2023') from April 14 to 19, 2023....JAB-23425 has significant antitumor effect on cancer models with multiple KRAS mutations (such as G12D, G12V, and G13D) and amplification of wild type KRAS, and has no inhibitory effect on KRAS-independent cells."

Preclinical • Oncology • Solid Tumor